Patient preferences regarding side effects of chemotherapy for ovarian cancer: Do they change over time?

Objective. The goals of this study were to: (1) systematically evaluate patient preferences regarding side effects of high-dose chemotherapy with stem cell support for treatment of advanced ovarian cancer; and (2) assess whether patients' preferences changed over time. Methods. Forty patients with stage III or IV disease were enrolled in this study. Patients' preferences regarding 12 health states (side effects) were assessed using visual analogue scale (VAS) and time trade-off (TTO) methods during mobilization chemotherapy (T₁) and 6-7 weeks later after high-dose chemotherapy and stem cell transplant (T₂). Each assessment involved a 45-min interview conducted at the patient's bedside. Results. The three most preferred health states were no evidence of disease (NED), a chemotherapy with few or no side effects, and alopecia, while the least preferred health states were chemotherapy with multiple severe side effects, hepatotoxicity, and nausea and vomiting. These results were observed at both T₁ and T₂ using both preference assessment methods. Pancytopenia scores significantly increased from T₁ to T₂ using the VAS method (P < 0.05), but decreased using the TTO method. Conclusions. Chemotherapy-experienced women with ovarian cancer have consistent preferences for the best and worst health states associated with the side effects of chemotherapy. Patients are more averse to nausea and vomiting than many other symptoms. Women's perceptions of pancytopenia may be dependent upon the number of prior cycles of chemotherapy and site of care for anemia, thrombocytopenia, and febrile neutropenia.